Plant Name: Chlamydomonas reinhardtii
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; FFAR1; P2RY1; P2RY2; FFAR4; | |
| GRM1; GRM3; GRM2; GRM8; GRM4; GRM5; | |
| TSHR; | |
| HDAC1; | |
| TDP1; FBP1; BLM; ADK; DAO; HSD17B10; HPGD; ALOX15; ALDH1A1; | |
| GRIA4; GRIA2; GRIK3; GRIK5; GRIK1; GRIK2; | |
| SRC; | |
| CA2; CA12; CA1; CA5A; CA5B; CA6; | |
| PPARA; PPARD; PPARG; | |
| NR1H4; | |
| CASP1; CASP7; | |
| TLR2; | |
| TP53; STAT6; | |
| ABCB1; | |
| SLC28A2; SLC28A1; SLC28A3; SLC1A1; | |
| LMNA; FABP3; FABP5; FABP4; FABP2; MAPT; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP3A4; |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | FBP1 | Fructose-1,6-bisphosphatase | P09467 | CHEMBL3975 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | DAO | D-amino-acid oxidase | P14920 | CHEMBL5485 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Histone deacetylase | HDAC1 | Histone deacetylase 1 | Q13547 | CHEMBL325 |
| Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
| Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
| Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
| Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
| Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
| Ionotropic glutamate receptor | GRIK2 | Glutamate receptor ionotropic kainate 2 | Q13002 | CHEMBL3683 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | P2RY1 | Purinergic receptor P2Y1 | P47900 | CHEMBL4315 |
| Small molecule receptor (family A GPCR) | P2RY2 | Purinergic receptor P2Y2 | P41231 | CHEMBL4398 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
| Small molecule receptor (family C GPCR) | GRM3 | Metabotropic glutamate receptor 3 | Q14832 | CHEMBL2888 |
| Small molecule receptor (family C GPCR) | GRM2 | Metabotropic glutamate receptor 2 | Q14416 | CHEMBL5137 |
| Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
| Small molecule receptor (family C GPCR) | GRM4 | Metabotropic glutamate receptor 4 | Q14833 | CHEMBL2736 |
| Small molecule receptor (family C GPCR) | GRM5 | Metabotropic glutamate receptor 5 | P41594 | CHEMBL3227 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | Unclassified; | GO:0004872; receptor activity | 1.382E-13 | 3.762E-10 | ADORA1, ADORA2A, ADORA3, FFAR1, FFAR4, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, HPGD, NR1H4, P2RY1, P2RY2, PPARA, PPARD, PPARG, TLR2, TSHR |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.402E-12 | 4.608E-09 | CA1, CA12, CA2, CA5A, CA5B, CA6 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 8.248E-12 | 8.164E-09 | ADORA1, ADORA2A, ADORA3, FFAR1, FFAR4, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, HPGD, P2RY1, P2RY2, PPARG, TSHR |
| MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 1.827E-11 | 1.420E-08 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 3.851E-11 | 2.466E-08 | ADORA1, ADORA2A, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 1.524E-10 | 9.482E-08 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 4.195E-10 | 2.404E-07 | GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.259E-09 | 6.091E-07 | CA1, CA12, CA2, CA5A, CA5B, CA6 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 2.923E-09 | 1.224E-06 | ADORA1, ADORA2A, ADORA3, P2RY1 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.475E-09 | 1.740E-06 | CA1, CA12, CA2, CA5A, CA5B, CA6 |
| CC | GO:0043226; organelle | GO:0014069; postsynaptic density | 9.804E-09 | 3.276E-06 | ADORA1, ADORA2A, GRIK2, GRIK5, GRM1, GRM3, GRM5, P2RY1, SRC |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.047E-08 | 3.305E-06 | ADORA1, ADORA2A, ADORA3, P2RY1 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 1.182E-07 | 2.932E-05 | ADORA1, ADORA2A, CA2, GRIA2, GRIA4, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM5, HDAC1, MAPT, P2RY1, SMN1, SMN2, SRC, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0031000; response to caffeine | 2.491E-07 | 5.832E-05 | ADORA2A, HDAC1, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.013E-06 | 1.886E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 3.367E-06 | 5.091E-04 | ABCB1, CA2, GRM5 |
| BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 3.367E-06 | 5.091E-04 | PPARG, SRC, TP53 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.194E-06 | 8.816E-04 | BLM, CA1, CA12, CA2, CA5A, CA5B, CA6, NR1H4, PPARA, PPARD, PPARG, TP53 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 8.052E-06 | 1.076E-03 | ADORA2A, CASP1, FFAR1, NR1H4, PPARD, SRC, TLR2 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 9.488E-06 | 1.216E-03 | SLC28A2, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 9.488E-06 | 1.216E-03 | SLC28A1, SLC28A3 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 9.488E-06 | 1.216E-03 | SLC28A2, SLC28A3 |
| MF | GO:0060089; molecular transducer activity | GO:0001641; group II metabotropic glutamate receptor activity | 9.488E-06 | 1.216E-03 | GRM2, GRM3 |
| BP | GO:0023052; signaling | GO:0051967; negative regulation of synaptic transmission, glutamatergic | 1.012E-05 | 1.289E-03 | ADORA1, GRIK2, GRIK3 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 1.328E-05 | 1.634E-03 | ADORA1, ADORA2A, PPARA, PPARG, TP53 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 1.550E-05 | 1.865E-03 | ADORA1, ADORA2A, MAPT |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.605E-05 | 1.910E-03 | NR1H4, PPARA, PPARD, PPARG |
| BP | GO:0032501; multicellular organismal process | GO:0048714; positive regulation of oligodendrocyte differentiation | 2.249E-05 | 2.565E-03 | HDAC1, PPARG, TLR2 |
| BP | Unclassified; | GO:0099566; regulation of postsynaptic cytosolic calcium ion concentration | 2.841E-05 | 3.017E-03 | GRM1, GRM5 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 2.841E-05 | 3.017E-03 | SLC28A1, SLC28A3 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 2.841E-05 | 3.017E-03 | SLC28A1, SLC28A3 |
| MF | GO:0060089; molecular transducer activity | GO:0099583; neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration | 2.841E-05 | 3.017E-03 | GRM1, GRM5 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 2.841E-05 | 3.017E-03 | ADORA1, ADORA2A |
| CC | GO:0032991; macromolecular complex | GO:0032983; kainate selective glutamate receptor complex | 2.841E-05 | 3.017E-03 | GRIK2, GRIK5 |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 2.883E-05 | 3.032E-03 | GRIK2, GRIK3, GRIK5, SMN1, SMN2 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 3.369E-05 | 3.477E-03 | NR1H4, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.642E-05 | 3.688E-03 | HDAC1, PPARG, TP53 |
| BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 3.944E-05 | 3.939E-03 | ADORA1, ALOX15, CASP1, FFAR4, GRM1, GRM4, HDAC1, P2RY1, PPARD, SRC, TLR2, TP53 |
| BP | GO:0007610; behavior | GO:0007610; behavior | 4.053E-05 | 3.989E-03 | ADORA2A, GRIK2, GRM1, GRM5, MAPT, P2RY1, PPARA, TLR2, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 4.140E-05 | 3.989E-03 | ADORA1, ADORA2A, P2RY1, P2RY2, PPARD |
| CC | GO:0044456; synapse part | GO:0043195; terminal bouton | 4.101E-05 | 3.989E-03 | ADORA1, GRIK2, GRIK3, GRIK5 |
| BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 4.302E-05 | 4.091E-03 | ADORA2A, FFAR1, NR1H4, P2RY1, PPARD |
| BP | GO:0065007; biological regulation | GO:0051881; regulation of mitochondrial membrane potential | 4.649E-05 | 4.383E-03 | ADORA2A, CASP1, MAPT, SRC |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 5.189E-05 | 4.808E-03 | NR1H4, PPARA, PPARD, PPARG, SRC |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 5.570E-05 | 5.084E-03 | FABP3, PPARA, PPARD, PPARG |
| MF | GO:0005215; transporter activity | GO:0004971; AMPA glutamate receptor activity | 5.670E-05 | 5.123E-03 | GRIA2, GRIA4 |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 7.135E-05 | 6.265E-03 | FABP3, PPARA, PPARG, SRC, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 8.667E-05 | 7.459E-03 | ALOX15, BLM, CA2, FABP4, FBP1, SRC, STAT6, TP53 |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 9.432E-05 | 7.960E-03 | PPARA, PPARG |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 9.609E-05 | 8.047E-03 | ALOX15, PPARA, PPARD, TP53 |
| BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 6.959E-17 | 3.788E-13 | GRIK3, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.109E-19 | 1.608E-17 | GRIA2; GRIK5; GRIK3; GRIK1; GRIK2; TSHR; GRM1; GRM3; GRM2; GRM5; GRM4; ADORA2A; ADORA3; P2RY2; P2RY1; GRM8; ADORA1; GRIA4 |
| hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 1.370E-17 | 9.930E-16 | GRIA2; GRIK5; SLC1A1; GRIK3; GRIK1; GRIK2; GRM1; GRM3; GRM2; GRM5; GRM4; GRM8; GRIA4 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.800E-12 | 3.287E-10 | CA12; CA1; CA5B; CA2; CA5A; CA6 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.422E-09 | 5.155E-08 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 4.562E-06 | 1.323E-04 | GRM3; GRM2; GRM5; GRM4; GRM8; GRM1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.881E-05 | 6.963E-04 | GRIA2; ADORA2A; ADORA1; PPARA; TSHR; GRIA4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.119E-05 | 1.267E-03 | ABCB1; CA2; NR1H4; CYP3A4 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 2.405E-04 | 4.358E-03 | GRIA2; GRM5; GRM1; GRIA4 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 4.287E-04 | 6.907E-03 | GRM3; GRIA2; GRM2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 9.677E-04 | 1.037E-02 | SRC; STAT6; TP53; TLR2 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 6.354E-04 | 7.678E-03 | FABP4; ADORA1; TSHR |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 4.825E-04 | 6.996E-03 | GRIA2; CASP1; TP53 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 6.027E-04 | 7.678E-03 | CASP7; CASP1; TLR2 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 1.073E-03 | 1.037E-02 | GRIA2; HDAC1; GRIA4 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 1.027E-03 | 1.037E-02 | GRIA2; GRM5; GRM1 |
| hsa04742 | Taste transduction_Homo sapiens_hsa04742 | 1.989E-03 | 1.782E-02 | GRM4; P2RY1; GRM1 |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 2.689E-03 | 2.052E-02 | GRM5; HDAC1; PPARG; TP53 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.089E-03 | 1.782E-02 | HPGD; HDAC1; PPARG; TP53 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 2.350E-03 | 1.893E-02 | GRM5; SRC; GRM1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 5.365E-03 | 3.536E-02 | SRC; HDAC1; TP53 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.588E-03 | 4.789E-02 | CASP7; LMNA; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.621E-03 | 3.544E-02 | ADORA3; ADORA1; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.411E-03 | 2.355E-02 | PPARG; TP53 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 6.732E-03 | 3.904E-02 | SRC; TP53 |
| hsa05033 | Nicotine addiction_Homo sapiens_hsa05033 | 6.416E-03 | 3.876E-02 | GRIA2; GRIA4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.411E-03 | 2.355E-02 | ALOX15; CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | GRM3; GRM2; GRM2; GRM5; GRM5 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | P2RY2 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; SRC |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| H00-H59: Diseases of the eye and adnexa | Dry eye disease | H16.229 | P2RY2 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | ABCB1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; SRC |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | GRIA4; GRIA2; ADORA2A; ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | GRIK1; GRM1; ADORA2A; ADK |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | GRM5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Autism | F84.0 | GRM5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | ABCB1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | GRM2 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PPARG; PPARG |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | GRIK1; GRM1; ADORA2A; ADORA1; GRM5 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | GRIK1; GRM1; GRM4; GRM5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ABCB1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | GRM2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | GRM1; GRM3; GRM2 |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | ABCB1; ADORA3; CA1; TP53; TLR2; SRC |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Fragile X syndrome | F02.3, G20, Q99.2 | GRM5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | ABCB1; TP53; TLR2; SRC |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ABCB1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | GRM2; GRM5; PPARD; MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| G00-G99: Diseases of the nervous system G00-G99 | Chronic neuropathic pain | G64, G90.0, K21, R52, G89 | GRM5; GRM5 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | GRM3; GRM2; GRM4; GRM5; CYP3A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DAO; ADORA1; MAPT |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| K00-K95: Diseases of the digestive system | Constipation | K59.0 | P2RY2 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GRM1; GRM3; GRM2; GRM5; MAPT; PPARG; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | SRC |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| NA: NA | GERD | NA | GRM5 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | GRIK1; GRIK1; CASP1; ADK |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | GRIK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | P2RY1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; FFAR1; PPARG |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | P2RY2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | GRM2; GRM5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADORA2A; ADORA1; CA1; CA1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |